U.S. FDA Accepts and Grants Priority Review for Eisai’s Biologics License Application of Lecanemab
TOKYO, Jul 6, 2022 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics...